Insight Molecular Diagnostics
IMDX
33 hedge funds and large institutions have $22.4M invested in Insight Molecular Diagnostics in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 14 closing their positions.
53% more capital inflows, than outflows
Capital inflows: $1.12M | Capital outflows: $729K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.2% less ownership
Funds ownership: 27.48% → 22.28% (-5.2%)
15% less funds holding
Funds holding: 39 → 33 (-6)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
+$456K |
| 2 |
Millennium Management
New York
|
+$305K |
| 3 |
Element Capital Management
New York
|
+$144K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$97.6K |
| 5 |
Williams Jones & Associates
New York
|
+$37.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$342K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$83.4K |
| 3 |
Destination Wealth Management
Walnut Creek,
California
|
-$62K |
| 4 |
State Street
Boston,
Massachusetts
|
-$39K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$37K |
IMDX Hedge Fund Activity: Q2 2018 in Review
33 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2018, worth a combined $22.4M — up 23% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IMDX and 8 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 4 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $456K. The largest seller was BlackRock, cutting an estimated $342K.
- 33 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2018, down from 39 in Q1 2018.
- Funds reported $22.4M of Insight Molecular Diagnostics stock for Q2 2018, up 23% quarter-over-quarter.
- 8 funds opened new Insight Molecular Diagnostics positions in Q2 2018 and 14 closed out, a net change of -6 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2018 was Bridgeway Capital Management, an estimated $456K added.
- The largest Insight Molecular Diagnostics seller in Q2 2018 was BlackRock, an estimated $342K sold.
Based on aggregated 13F filings for Q2 2018.